Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
PepGen Inc (PEPG)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.32-5.31%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PEPG yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain strong cash runway into 2H 2027 | A primary condition in PepGen Inc's published investment case. The stated target is Sufficient cash to fund operations through second half of 2027. | Intact | Cash falls short of funding operations through 2H 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative growth, centered on clinical results rather than current earnings. The long-term thesis is still in a watch state: management is tracking its trial timelines, but the evidence snapshot gives low confidence and flags high risk.
Valuation evidence is thin, and the company is loss-making, so a peer-based view of whether it is cheap, fair, or expensive is not supported here. The evidence does not show what the market already assumes; recent earnings beats and stronger sector context are positive signals, but they do not establish that clinical or financial expectations are modest.
Near term, the company remains loss-making and has reported no revenue or operating income in the evidence. Cash declined from the first to the second quarter of 2026, while management says runway is sufficient into 4Q 2027; trial updates are expected in November 2026 and 1H 2027. Recent earnings beats are encouraging, but weaker industry-relative performance and the risk of guidance cuts remain concerns.
The multi-year thesis depends on FREEDOM2 results arriving on schedule and supporting further clinical progress, while cash remains sufficient to reach key milestones. Near term, a guidance cut or further weakening in jobs data would add risk; continued strength from healthcare bellwethers could support sector momentum.
Over the next 1 to 3 years, PEPG’s case rests on clinical progress and managing cash through upcoming milestones, not on established earnings. The evidence is mixed and low-confidence, with high risk and meaningful uncertainty around results and guidance. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: “Based on currently planned operations, PepGen believes that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operations into the fourth quarter of 2027.” “Financial Results for the Three Months Ended June 30, 2026 • Cash, Cash Equivalents and Marketable Securities were $117.2 million as of June 30, 2026.”
Report FREEDOM2 10 mg/kg clinical results in 2H 2026 | They plan to report key clinical results in late 2026 and 2027. | Intact | Failure to report or negative results from FREEDOM2 10 mg/kg cohort in 2H 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Report FREEDOM2 12.5 mg/kg clinical results in 2027 | They plan to report key clinical results in late 2026 and 2027. | Intact | Failure to report or negative results from FREEDOM2 12.5 mg/kg cohort in 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.23 → $-1.11 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.23 | $0 | 7 / 7 |
| 2026-07-25 | $-1.23 | $0 | 7 / 7 |
| 2026-07-26 | $-1.23 | $0 | 7 / 7 |
| 2026-07-27 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-07-28 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-07-29 | $-1.23 | $0 | 7 / 7 |
| 2026-07-30 | $-1.23 | $0 | 7 / 7 |
| 2026-07-31 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-08-01 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-08-02 | $-1.23 | $0 | 7 / 7 |
| 2026-08-03 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-08-04 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-08-05 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-08-06 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-08-07 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-08-08 | $-1.05 | $0 | 6 / 7 |
| 2026-08-09 | $-1.04 | $0 | 6 / 7 |
| 2026-08-10 | $-1.04 | $0 | 6 / 7 |
| 2026-08-12 | $-1.04 | $0 | 6 / 7 |
| 2026-08-13 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-08-14 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-08-15 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-08-16 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-08-17 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-08-18 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-08-19 | $-1.19 | $4,612,500 | 6 / 4 |
| 2026-08-20 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-08-21 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-08-22 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-08-23 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-08-24 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-08-25 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-08-26 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-08-27 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-08-28 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-08-29 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-08-30 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-08-31 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-01 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-02 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-03 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-04 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-05 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-06 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-07 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-08 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-09 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-10 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-11 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-12 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-13 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-14 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-15 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-16 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-17 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-18 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-19 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-20 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-21 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-22 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-23 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-24 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-25 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-26 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-27 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-28 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-29 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-09-30 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-10-01 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-10-02 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-10-03 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-10-04 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-10-05 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-10-06 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-10-07 | $-1.09 | $4,612,500 | 6 / 4 |
| 2026-10-08 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-09 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-10 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-11 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-12 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-13 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-14 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-15 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-16 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-17 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-18 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-19 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-20 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-21 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-22 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-23 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-24 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-25 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-26 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-27 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-28 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-29 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-30 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-10-31 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-11-01 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-11-02 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-11-03 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-11-04 | $-1.11 | $4,612,500 | 6 / 3 |
| 2026-11-05 | $-1.11 | $4,612,500 | 6 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.